Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07079475). This is a study registration, not published results. Lead sponsor: Dizal Pharmaceuticals. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 220 participants (ESTIMATED). Conditions: Non-Small Cell Lung Cancer. Interventions: DRUG: DZD6008; DRUG: Sunvozertinib; DRUG: Osimertinib. Primary outcome measures: Part A: To assess safety and tolerability , Through the study completion, an average of around 2 years; Part A: To assess safety and tolerability , 21 days after the first dose; Part B: To assess anti-tumor activity , Through the study completion, an average of around 2 years. Brief summary: This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the treatment. It will also measure the levels of two drugs in the body and preliminarily assess the anti-tumor activity with the combination treatment